Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

David Wyles

Concepts (252)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antiviral Agents
60
2026
765
11.220
 Why?
Hepatitis C, Chronic
32
2025
152
8.970
 Why?
Hepacivirus
49
2026
243
8.330
 Why?
Hepatitis C
30
2026
254
8.130
 Why?
Benzimidazoles
19
2026
187
4.380
 Why?
Drug Resistance, Viral
18
2025
123
3.850
 Why?
Coinfection
15
2020
141
2.860
 Why?
HIV Infections
28
2022
3148
2.750
 Why?
Quinoxalines
8
2026
64
2.380
 Why?
Ribavirin
15
2020
80
2.270
 Why?
Sulfonamides
14
2026
579
2.270
 Why?
Sofosbuvir
16
2022
61
2.180
 Why?
Fluorenes
7
2020
46
2.120
 Why?
Liver Cirrhosis
8
2020
287
2.070
 Why?
Viral Nonstructural Proteins
10
2025
65
2.070
 Why?
Drug Therapy, Combination
26
2020
1044
1.740
 Why?
Uridine Monophosphate
5
2016
16
1.610
 Why?
Carbamates
9
2020
51
1.380
 Why?
Anti-Retroviral Agents
5
2019
250
1.350
 Why?
Protease Inhibitors
10
2020
101
1.330
 Why?
Pyrrolidines
10
2026
123
1.320
 Why?
Hepatitis B, Chronic
3
2019
22
1.280
 Why?
Proline
12
2026
82
1.250
 Why?
Genotype
21
2025
1847
1.140
 Why?
Sustained Virologic Response
12
2026
46
1.140
 Why?
Congresses as Topic
3
2021
221
1.120
 Why?
Hepatitis, Viral, Human
3
2021
20
1.100
 Why?
Cyclopropanes
12
2026
83
0.980
 Why?
Lactams, Macrocyclic
11
2026
51
0.920
 Why?
Drug Users
2
2024
42
0.920
 Why?
Heterocyclic Compounds, 4 or More Rings
3
2017
23
0.760
 Why?
HIV-1
8
2020
897
0.740
 Why?
Respiratory Insufficiency
1
2026
324
0.730
 Why?
Treatment Failure
6
2025
365
0.710
 Why?
Virus Replication
7
2012
525
0.700
 Why?
Pyridines
1
2026
603
0.690
 Why?
RNA, Viral
10
2026
689
0.670
 Why?
Disease Eradication
1
2020
5
0.660
 Why?
Organophosphonates
4
2011
97
0.650
 Why?
Humans
79
2026
144665
0.650
 Why?
Homosexuality, Male
2
2021
223
0.620
 Why?
Valine
7
2020
80
0.600
 Why?
Anti-HIV Agents
6
2020
890
0.580
 Why?
Treatment Outcome
20
2026
11734
0.550
 Why?
Aminoisobutyric Acids
6
2026
9
0.550
 Why?
Middle Aged
34
2026
35968
0.550
 Why?
Nucleic Acid Synthesis Inhibitors
2
2015
16
0.530
 Why?
Leucine
6
2026
116
0.520
 Why?
Ritonavir
6
2020
75
0.510
 Why?
Imidazoles
2
2015
246
0.510
 Why?
Darunavir
1
2017
20
0.500
 Why?
Male
43
2026
72425
0.490
 Why?
Adult
33
2026
40486
0.480
 Why?
Uracil
5
2020
36
0.480
 Why?
Antiretroviral Therapy, Highly Active
3
2015
278
0.470
 Why?
Anilides
5
2020
84
0.460
 Why?
Female
41
2026
78301
0.440
 Why?
Education, Medical, Continuing
1
2016
133
0.440
 Why?
Biomedical Research
1
2021
712
0.420
 Why?
Oligopeptides
2
2013
266
0.410
 Why?
Pyridazines
1
2014
57
0.410
 Why?
Adenine
4
2020
337
0.410
 Why?
2-Naphthylamine
5
2020
6
0.400
 Why?
Viral Load
7
2020
528
0.400
 Why?
Macrocyclic Compounds
3
2019
15
0.390
 Why?
Purines
1
2014
187
0.380
 Why?
Aged
18
2026
25955
0.380
 Why?
Quinolines
1
2014
192
0.380
 Why?
Replicon
3
2009
15
0.380
 Why?
Liver
1
2021
1889
0.370
 Why?
Scavenger Receptors, Class B
1
2012
14
0.360
 Why?
Disease Management
1
2016
650
0.360
 Why?
Mass Screening
4
2025
1348
0.320
 Why?
Retreatment
2
2021
77
0.320
 Why?
Drug Synergism
3
2008
352
0.310
 Why?
Acquired Immunodeficiency Syndrome
2
2020
235
0.280
 Why?
Dideoxynucleosides
2
2005
24
0.280
 Why?
Liver Diseases
2
2016
304
0.270
 Why?
Interferon-alpha
4
2013
194
0.270
 Why?
Nucleoside-Triphosphatase
3
2017
14
0.270
 Why?
Cytokines
1
2015
2045
0.260
 Why?
DEAD-box RNA Helicases
3
2017
89
0.250
 Why?
Serine Endopeptidases
3
2017
129
0.250
 Why?
Amino Acid Substitution
2
2018
303
0.250
 Why?
Cytosine
2
2009
49
0.240
 Why?
Indolizines
1
2026
13
0.240
 Why?
Global Health
2
2020
401
0.240
 Why?
Hospitalization
3
2026
2446
0.240
 Why?
Hepatitis B virus
2
2019
33
0.220
 Why?
HIV
2
2019
248
0.220
 Why?
Double-Blind Method
3
2026
2033
0.210
 Why?
Hepatitis
1
2004
43
0.210
 Why?
Herpes Simplex
1
2005
98
0.210
 Why?
Alanine
2
2021
170
0.200
 Why?
Interferons
2
2015
185
0.190
 Why?
Prevalence
3
2019
2839
0.190
 Why?
Mutation, Missense
3
2014
338
0.180
 Why?
Hospitals
2
2024
729
0.180
 Why?
Pyrazoles
1
2026
512
0.180
 Why?
Interferon beta-1a
1
2021
14
0.180
 Why?
Young Adult
10
2019
14119
0.170
 Why?
Hepatitis A
1
2021
25
0.170
 Why?
Adenosine Monophosphate
1
2021
86
0.170
 Why?
Phylogeny
1
2025
1024
0.160
 Why?
Feasibility Studies
1
2025
1103
0.160
 Why?
Tenofovir
2
2020
295
0.160
 Why?
Hepatitis B
1
2021
65
0.160
 Why?
World Health Organization
1
2020
104
0.160
 Why?
Benzopyrans
2
2017
30
0.160
 Why?
Disease Progression
2
2019
2847
0.150
 Why?
Data Interpretation, Statistical
2
2018
368
0.150
 Why?
Drug Combinations
4
2026
393
0.150
 Why?
Polyethylene Glycols
2
2015
653
0.150
 Why?
Esters
2
2009
72
0.140
 Why?
CD4 Lymphocyte Count
2
2017
277
0.140
 Why?
Ribosomes
2
2010
196
0.140
 Why?
United States
10
2025
16018
0.140
 Why?
Immunologic Factors
1
2020
259
0.140
 Why?
Emergency Service, Hospital
3
2025
2325
0.140
 Why?
Nucleic Acid Conformation
4
2014
728
0.130
 Why?
Alanine Transaminase
1
2018
151
0.130
 Why?
DNA, Viral
1
2019
357
0.130
 Why?
Genes, Viral
1
2016
89
0.120
 Why?
DNA Mutational Analysis
1
2018
409
0.120
 Why?
Molecular Structure
2
2008
495
0.120
 Why?
High-Throughput Nucleotide Sequencing
2
2016
552
0.120
 Why?
Mutation
2
2018
4081
0.120
 Why?
Patient Compliance
1
2020
587
0.120
 Why?
Survival Analysis
1
2019
1370
0.120
 Why?
Dose-Response Relationship, Drug
2
2017
2019
0.110
 Why?
Adolescent
5
2022
22405
0.110
 Why?
Regulatory Sequences, Ribonucleic Acid
1
2014
18
0.110
 Why?
AIDS-Related Opportunistic Infections
1
2015
130
0.110
 Why?
Chemokines
1
2015
218
0.110
 Why?
Chemokine CXCL10
1
2014
39
0.100
 Why?
Drug Interactions
1
2015
401
0.100
 Why?
Risk Assessment
2
2025
3729
0.100
 Why?
Fibrosis
1
2016
547
0.100
 Why?
Opiate Substitution Treatment
1
2016
186
0.100
 Why?
Phenylenediamines
1
2013
14
0.100
 Why?
Viral Proteins
2
2014
353
0.100
 Why?
Prospective Studies
5
2025
7994
0.100
 Why?
Microbial Sensitivity Tests
2
2012
373
0.090
 Why?
Prognosis
2
2019
4312
0.090
 Why?
Equivalence Trials as Topic
2
2023
36
0.090
 Why?
Quality of Life
1
2025
3183
0.090
 Why?
Drug Discovery
1
2013
153
0.090
 Why?
Administration, Oral
1
2014
851
0.090
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2013
259
0.080
 Why?
Case-Control Studies
2
2017
3603
0.080
 Why?
Cohort Studies
5
2024
5957
0.080
 Why?
Models, Molecular
3
2012
1610
0.080
 Why?
Mental Disorders
1
2020
1154
0.080
 Why?
Prodrugs
1
2011
52
0.080
 Why?
Nucleosides
1
2010
25
0.080
 Why?
Riboswitch
1
2012
63
0.080
 Why?
Telemedicine
1
2020
957
0.080
 Why?
Japan
2
2021
145
0.080
 Why?
Drug Administration Schedule
3
2017
779
0.080
 Why?
Cell Line, Tumor
2
2008
3523
0.070
 Why?
Drug Design
1
2010
176
0.070
 Why?
Biomarkers
1
2020
4261
0.070
 Why?
Cell Line
2
2012
2821
0.070
 Why?
Randomized Controlled Trials as Topic
3
2023
1742
0.070
 Why?
Piperidines
1
2010
219
0.070
 Why?
Phenylthiourea
1
2008
5
0.070
 Why?
Practice Guidelines as Topic
1
2016
1569
0.070
 Why?
Body Mass Index
1
2017
2419
0.070
 Why?
Immunity, Innate
1
2014
843
0.070
 Why?
Plasmids
1
2009
375
0.070
 Why?
Structure-Activity Relationship
1
2009
564
0.070
 Why?
Inhibitory Concentration 50
1
2006
90
0.060
 Why?
Luciferases
1
2006
152
0.060
 Why?
Genes, Reporter
1
2006
276
0.060
 Why?
Thailand
1
2025
18
0.060
 Why?
Saquinavir
1
2004
1
0.060
 Why?
Simplexvirus
1
2005
82
0.060
 Why?
Drug Labeling
1
2005
37
0.050
 Why?
Indinavir
1
2004
7
0.050
 Why?
Nelfinavir
1
2004
8
0.050
 Why?
Nevirapine
1
2004
18
0.050
 Why?
Uganda
1
2025
92
0.050
 Why?
Benzoxazines
1
2004
31
0.050
 Why?
Oxazines
1
2004
37
0.050
 Why?
Pandemics
2
2024
1700
0.050
 Why?
Lopinavir
1
2004
30
0.050
 Why?
Brazil
1
2025
182
0.050
 Why?
Zidovudine
1
2004
77
0.050
 Why?
Liver Function Tests
1
2004
105
0.050
 Why?
Alkynes
1
2004
66
0.050
 Why?
Transfection
1
2006
924
0.050
 Why?
Reverse Transcriptase Inhibitors
1
2004
87
0.050
 Why?
Time Factors
1
2015
7140
0.050
 Why?
Bone Marrow Transplantation
1
2005
293
0.050
 Why?
Pregnancy
1
2017
7122
0.050
 Why?
Pyrimidinones
1
2004
125
0.050
 Why?
Recombinant Fusion Proteins
1
2006
667
0.050
 Why?
South Africa
1
2025
265
0.050
 Why?
Carcinoma, Hepatocellular
1
2006
370
0.050
 Why?
Polyphosphates
1
2022
45
0.040
 Why?
Singapore
1
2021
27
0.040
 Why?
Republic of Korea
1
2021
42
0.040
 Why?
Pragmatic Clinical Trials as Topic
1
2022
133
0.040
 Why?
Dried Blood Spot Testing
1
2022
126
0.040
 Why?
Mexico
1
2021
234
0.040
 Why?
Retrospective Studies
5
2019
17147
0.040
 Why?
Multicenter Studies as Topic
1
2022
408
0.040
 Why?
Protein Biosynthesis
2
2014
455
0.040
 Why?
Liver Neoplasms
1
2006
777
0.040
 Why?
Raltegravir Potassium
1
2019
18
0.040
 Why?
Clinical Trials, Phase II as Topic
1
2019
76
0.040
 Why?
Clinical Trials, Phase III as Topic
1
2019
116
0.040
 Why?
Intensive Care Units
1
2024
915
0.030
 Why?
Drug Resistance, Multiple, Viral
1
2017
10
0.030
 Why?
Kinetics
1
2020
1603
0.030
 Why?
Longitudinal Studies
1
2024
2942
0.030
 Why?
Oxygen
1
2021
984
0.030
 Why?
Medicaid
1
2020
464
0.030
 Why?
Program Evaluation
1
2020
941
0.030
 Why?
Incidence
2
2013
2892
0.030
 Why?
RNA
1
2022
926
0.030
 Why?
Cell-Free System
1
2014
53
0.030
 Why?
Hepatitis C Antibodies
1
2014
11
0.030
 Why?
Spain
1
2014
49
0.030
 Why?
Polymorphism, Genetic
1
2017
613
0.030
 Why?
Enzyme-Linked Immunosorbent Assay
1
2016
835
0.030
 Why?
Withholding Treatment
1
2013
80
0.020
 Why?
Patient Acceptance of Health Care
1
2020
881
0.020
 Why?
Patient Care
1
2014
118
0.020
 Why?
Risk Factors
2
2020
10796
0.020
 Why?
Early Diagnosis
1
2014
249
0.020
 Why?
Aged, 80 and over
2
2019
8283
0.020
 Why?
Patient Reported Outcome Measures
1
2017
496
0.020
 Why?
Plasma
1
2014
223
0.020
 Why?
Fluorescence Resonance Energy Transfer
1
2012
177
0.020
 Why?
Virus Internalization
1
2010
65
0.020
 Why?
Ligands
1
2012
662
0.020
 Why?
Recombinant Proteins
1
2013
1363
0.020
 Why?
Magnesium
1
2009
155
0.020
 Why?
Pilot Projects
1
2015
1886
0.020
 Why?
Lamivudine
1
2009
65
0.020
 Why?
Referral and Consultation
1
2014
852
0.020
 Why?
Logistic Models
1
2013
2114
0.020
 Why?
Genome, Viral
1
2009
218
0.020
 Why?
Phenotype
1
2014
3147
0.010
 Why?
Base Sequence
1
2009
2177
0.010
 Why?
Severity of Illness Index
1
2013
2922
0.010
 Why?
Mice, Transgenic
1
2009
2184
0.010
 Why?
Animals
2
2018
37948
0.010
 Why?
Substance-Related Disorders
1
2011
1090
0.010
 Why?
Signal Transduction
1
2009
5185
0.010
 Why?
Mice
1
2009
18261
0.010
 Why?
Wyles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (252) concept(s)
_
Co-Authors Expand Description
See all (20) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)